David Colpman has more than 30 years of biopharma business development and strategy experience, including as Head of Global Business Development at Shire Pharmaceuticals LLC where he led a series of strategic mergers, acquisitions, licensing and divestment programs. Mr. Colpman has also held senior business development roles with Novo Nordisk A/S, Boots Pharmaceuticals and GlaxoSmithKline Plc. Mr. Colpman currently serves on the boards of Orexo AB and HRA Pharma Ltd.